Pharmacogenetics and Genomics

Journal

Publication Venue For

  • Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia.  32:60-66. 2022
  • Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.  28:179-187. 2018
  • Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.  27:347-355. 2017
  • A systematic analysis and comparison of warfarin initiation strategies.  26:445-452. 2016
  • A genome-wide study of lipid response to fenofibrate in Caucasians: A combined analysis of the GOLDN and ACCORD studies.  26:324-333. 2016
  • A family-specific linkage analysis of blood lipid response to fenofibrate in the Genetics of Lipid Lowering Drug and Diet Network.  25:511-514. 2015
  • Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.  25:450-461. 2015
  • A human leukocyte antigen locus haplotype confers risk for allopurinol-related adverse effects in Caucasian patients with gout.  25:412-415. 2015
  • Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.  25:343-353. 2015
  • Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study.  24:556-563. 2014
  • FcγR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response.  23:455-462. 2013
  • Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.  22:750-757. 2012
  • Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.  22:858-867. 2012
  • Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.  22:367-372. 2012
  • Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men.  21:798-807. 2011
  • Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression.  17:897-905. 2007
  • Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4)..  17:773-782. 2007
  • The L84F polymorphism in the O6-methylguanine-DNA-methyltransferase (MGMT) gene is associated with increased hypoxanthine phosphoribosyltransferase (HPRT) mutant frequency in lymphocytes of tobacco smokers.  17:743-753. 2007
  • The discovery of new coding alleles of human CYP26A1 that are potentially defective in the metabolism of all-trans retinoic acid and their assessment in a recombinant cDNA expression system.  17:169-180. 2007
  • Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)..  15:201-209. 2005
  • The L84F and the I143V polymorphisms in the O6-methylguanine- DNA-methyltransferase (MGMT) gene increase human sensitivity to the genotoxic effects of the tobacco-specific nitrosamine carcinogen NNK.  15:571-578. 2005
  • Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method.  10:373-388. 2000

    • International Standard Serial Number (issn)

  • 0960-314X
  • 1744-6872

    • Electronic International Standard Serial Number (eissn)

  • 1744-6880